Supporting this, a 20-year U.S. cohort study (1999–2020) found that TNF antagonist use was associated with a significantly lower risk of CRC in IBD patients (adjusted OR: 0.69 for CD; 0.78 for UC) (78). This evidence concerns the gene TNF and inflammatory bowel disease.